Abstract: Heparin binding-epidermal growth factor-like growth factor（HB-EGF），a member of the EGF family of growth factors，exerts its diverse biological activities through activation of the EGFR. Recently studies revealed HB-EGF expression was significantly elevated in ovarian cancer and it played a key role in the development of tumor，so HB-EGF was considered as a potential target for ovarian cancer therapy. The features of HB-EGF and the research progress of HB-EGF specific inhibitor CRM197 in therapy of ovarian cancer will be reviewed. We will also discuss the future direction for the development of therapeutic strategies targeting CRM197 and MTI-MMP inhibitor，ADAMs inhibitor，paclitaxel respectively.

Key words: Ovarian neoplasms, Epidermal growth factor, Receptor, epidermal growth factor, Antineoplastic protocols, Heparin binding-epidermal growth factor-like growth factor